IP Library Granted Patent US 7,566,740
Granted Patent B2
US 7,566,740 · App. 10/317,633 · Granted Jul 28, 2009

Method of treating mucositis

Assignee: BML Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,566,740
App. No.
10/317,633
Granted
Jul 28, 2009
Kind
B2
Abstract

A method of treating mucositis in immunocompromised patients is disclosed which is based on contacting the affected area with an amount of composition which comprises triclosan and a cationic antibacterial agent in amounts which are effective to alleviate the symptoms of mucositis.

Claims (7)

1. A method of treating mucositis in an immunocompromised patient, said method comprising contacting a mucositis lesion in said patient with an amount of a composition which comprises triclosan and a cationic antibacterial agent which is effective to alleviate the symptoms of mucositis.

2. A method of treating mucositis as defined in claim 1 wherein the cationic agent is selected from the group consisting of chiorhexidine, cetylpyridium chloride, benzalkonium chloride, benzethonium chloride, methylbenzethonium chloride and domiphen bromide.

3. A method of treating mucositis as defined in claim 1 wherein the cationic agent is cetylpyridium chloride.

4. A method of treating mucositis as defined in claim 3 wherein the triclosan and cationic agent are combined in a liquid formulation with a solubilizer.

5. A method of treating mucositis as defined in claim 3 wherein the triclosan and the cationic agent are combined in a semi-solid formulation.

6. A method of treating mucositis in an immunocompromised patient, said method comprising contacting a mucositis lesion in said patient with an amount of a composition which consists essentially of triclosan and a cationic antibacterial agent in amounts which are effective to alleviate the symptoms of mucositis.

7. A method of treating mucositis in an immunocompromised patient, said method consisting essentially of contacting a mucositis lesion in said patient with an amount of a composition which consists essentially of triclosan and a cationic antibacterial agent which is effective to alleviate the symptoms of mucositis.

Assignments (6)
RELEASE OF PATENT SECURITY INTEREST Recorded Mar 3, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 032380/0198 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 25416/381 Recorded Jul 11, 2011
From: JPMORGAN CHASE BANK N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 026572/0148 →
SECURITY AGREEMENT Recorded Jul 7, 2011
From: ENDO PHARMACEUTICALS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
Reel/Frame 026557/0350 →
RELEASE OF PATENT SECURITY INTEREST RECORDED AT REEL/FRAME 23390/120 Recorded Dec 3, 2010
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: ENDO PHARMACEUTICALS INC.
Reel/Frame 025441/0305 →
SECURITY AGREEMENT Recorded Dec 1, 2010
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 025416/0381 →
SECURITY AGREEMENT Recorded Oct 19, 2009
From: ENDO PHARMACEUTICALS INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 023390/0120 →
Continuity (2)
Continuation 0916722500 · Oct 6, 1998
Related Publication 20030091515A1 · May 15, 2003